Back to Research Hub
Alto Neuroscience, Inc.
ANRO
$27.23+0.16 (+0.59%)
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress…
StreetsValue research for Alto Neuroscience, Inc. (ANRO)
Members get the full report for Alto Neuroscience, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.